Vacuum Device for Hemostasis in Obstetrics and Gynecology (HEMOGYN2)
Primary Purpose
Primary Postpartum Hemorrhage, Administration of Sulprostone, Vaginal Childbirth
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Hemostatic Intra-Uterine suction cup
Sponsored by
About this trial
This is an interventional other trial for Primary Postpartum Hemorrhage
Eligibility Criteria
Inclusion Criteria:
- women between 18 and 45 years old
- patient under loco-regional anesthesia
- patient who presents primary postpartum hemorrhage (blood loss ≥ 500ml) after a vaginal childbirth requiring administration of Nalador®.
- affiliation to the French social security system or equivalent
- patient who has signed a consent to participate
Exclusion Criteria:
- patient with a uterine malformation
- patient allergic to silicon
- patient under general anesthesia
- patient who delivered via caesarean section
- patient with fever or suspected infection during labor
- person deprived of freedom by judicial or administrative decision
- person hospitalized without their consent
- person under legal protection
- person hospitalized for psychiatric care
Sites / Locations
- University Hospital Grenoble
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Primary Hemostatic Intra-Uterine suction cup
Arm Description
Patients who present primary postpartum hemorrhage requiring administration of Nalador and the suction cup placed in the uterine cavity
Outcomes
Primary Outcome Measures
Evaluation of the feasibility of using the hemostatic intrauterine suction cup in patients who present primary PPH (blood loss ≥ 500ml) after a vaginal childbirth requiring the administration of Nalador®.
The primary outcome is composite and consists of 3 the following component outcomes:
Qualification of success or failure of the introduction of the suction cup in the uterine cavity
Qualification of success or failure to create negative pressure in the suction cup. The negative pressure is validated if vacuum is maintained for at least 30 seconds.
Qualification of success or failure of removing the suction cup in its entirety.
The feasibility of using the suction cup will be validated if success is obtained for the 3 component outcomes.
Secondary Outcome Measures
Evaluation of the ease of the placement of the suction cup by the clinician
Visual quantitative satisfaction scale
Evaluation of whether the bleeding stops after each time the suction cup is put under vacuum. For each patient, the cup may be put once or twice under vacuum.
Subjective evaluation of whether bleeding stops by the clinician after each time the suction cup is put under vacuum.
Evaluation of the ease of removal of the suction cup by the clinician
Visual quantitative satisfaction scale
Quantification of blood loss during delivery
Volume of blood collected in the container of the pump and in the collection bag from the beginning of the delivery until the removal of the suction cup
Evaluation of the number of patients for whom invasive treatment is necessary in order to stop the bleeding
Number of patients for whom embolization or surgery is indicated
Assessment of the duration of time required to place and remove the suction cup
Time duration for the placement and removal of the suction cup
Full Information
NCT ID
NCT02816203
First Posted
June 24, 2016
Last Updated
March 2, 2023
Sponsor
University Hospital, Grenoble
Collaborators
Clinical Investigation Centre for Innovative Technology Network, HEMOSQUID
1. Study Identification
Unique Protocol Identification Number
NCT02816203
Brief Title
Vacuum Device for Hemostasis in Obstetrics and Gynecology
Acronym
HEMOGYN2
Official Title
Vacuum Device for Hemostasis in Obstetrics and Gynecology. Feasibility Study for Postpartum Hemorrhage
Study Type
Interventional
2. Study Status
Record Verification Date
March 2023
Overall Recruitment Status
Completed
Study Start Date
August 2016 (Actual)
Primary Completion Date
December 2022 (Actual)
Study Completion Date
December 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Grenoble
Collaborators
Clinical Investigation Centre for Innovative Technology Network, HEMOSQUID
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Postpartum hemorrhage (PPH), is the leading cause of maternal mortality and is responsible for approximately 25% of maternal mortality deaths.It is defined as blood loss in excess of 500 ml following vaginal childbirth. Primary (immediate) PPH occurs within the first 24 hours after delivery.
In clinical practice, if after giving birth, the placenta is not expelled naturally, an active management should be triggered. After obstetric maneuvers therapeutic, options begin with uterotonic treatments before considering invasive treatments such as embolization, vessel ligation and hysterectomy. However, the morbidity associated with these techniques and the desire to preserve fertility mean that new therapeutic solutions have been conceived, which has recently led to the development of an innovative intrauterine hemostasis medical device : a hemostatic intrauterine suction cup.
Assuming that postpartum hemorrhages are mainly due to uterine atony, we propose in this biomedical research, the study of a new medical device. Our hypothesis is that the uterine walls will append to the walls of the suction cup after the latter is put under vacuum. The actuation of the suction cup will lead to the aspiration of all sides of the uterus.
Considering that postpartum haemorrhage is an emergency situation where vital prognosis of the patient is engaged, we selected to collect the consent of the patient using an emergengy procedure.
Detailed Description
In this study, as a first pass in human of this innovative non CE marked medical device, we aim to demonstrate the feasibility of using the hemostatic intrauterine suction cup for patients who present primary PPH (blood loss ≥ 500ml) after a vaginal delivery requiring administration of Nalador®. We will evaluate the placement of hemostatic suction cup in the uterus, the application of vacuum and its removal from the uterus.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Primary Postpartum Hemorrhage, Administration of Sulprostone, Vaginal Childbirth
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Primary Hemostatic Intra-Uterine suction cup
Arm Type
Experimental
Arm Description
Patients who present primary postpartum hemorrhage requiring administration of Nalador and the suction cup placed in the uterine cavity
Intervention Type
Device
Intervention Name(s)
Hemostatic Intra-Uterine suction cup
Intervention Description
The hemostatic intra-uterine suction cup is introduced to the uterine cavity and a negative pressure is applied into the device.
Primary Outcome Measure Information:
Title
Evaluation of the feasibility of using the hemostatic intrauterine suction cup in patients who present primary PPH (blood loss ≥ 500ml) after a vaginal childbirth requiring the administration of Nalador®.
Description
The primary outcome is composite and consists of 3 the following component outcomes:
Qualification of success or failure of the introduction of the suction cup in the uterine cavity
Qualification of success or failure to create negative pressure in the suction cup. The negative pressure is validated if vacuum is maintained for at least 30 seconds.
Qualification of success or failure of removing the suction cup in its entirety.
The feasibility of using the suction cup will be validated if success is obtained for the 3 component outcomes.
Time Frame
36 month
Secondary Outcome Measure Information:
Title
Evaluation of the ease of the placement of the suction cup by the clinician
Description
Visual quantitative satisfaction scale
Time Frame
36 month
Title
Evaluation of whether the bleeding stops after each time the suction cup is put under vacuum. For each patient, the cup may be put once or twice under vacuum.
Description
Subjective evaluation of whether bleeding stops by the clinician after each time the suction cup is put under vacuum.
Time Frame
36 month
Title
Evaluation of the ease of removal of the suction cup by the clinician
Description
Visual quantitative satisfaction scale
Time Frame
36 month
Title
Quantification of blood loss during delivery
Description
Volume of blood collected in the container of the pump and in the collection bag from the beginning of the delivery until the removal of the suction cup
Time Frame
36 month
Title
Evaluation of the number of patients for whom invasive treatment is necessary in order to stop the bleeding
Description
Number of patients for whom embolization or surgery is indicated
Time Frame
36 month
Title
Assessment of the duration of time required to place and remove the suction cup
Description
Time duration for the placement and removal of the suction cup
Time Frame
36 month
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
women between 18 and 45 years old
patient under loco-regional anesthesia
patient who presents primary postpartum hemorrhage (blood loss ≥ 500ml) after a vaginal childbirth requiring administration of Nalador®.
affiliation to the French social security system or equivalent
patient who has signed a consent to participate
Exclusion Criteria:
patient with a uterine malformation
patient allergic to silicon
patient under general anesthesia
patient who delivered via caesarean section
patient with fever or suspected infection during labor
person deprived of freedom by judicial or administrative decision
person hospitalized without their consent
person under legal protection
person hospitalized for psychiatric care
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Véronique Equy, MD
Organizational Affiliation
Clinic of Gynecology and Obstetrics, University Hospital Grenoble, France
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital Grenoble
City
Grenoble
ZIP/Postal Code
38043
Country
France
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Vacuum Device for Hemostasis in Obstetrics and Gynecology
We'll reach out to this number within 24 hrs